Levin Capital Strategies L.P. Purchases 245,123 Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Levin Capital Strategies L.P. grew its position in Alpha Tau Medical Ltd. (NASDAQ:DRTS) by 288.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 330,123 shares of the company’s stock after acquiring an additional 245,123 shares during the quarter. Levin Capital Strategies L.P. owned 0.48% of Alpha Tau Medical worth $994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of DRTS. Hoylecohen LLC purchased a new position in shares of Alpha Tau Medical during the 3rd quarter worth $1,020,000. Satovsky Asset Management LLC purchased a new stake in Alpha Tau Medical in the 4th quarter valued at approximately $176,000. Finally, Telemus Capital LLC purchased a new position in Alpha Tau Medical during the fourth quarter worth about $89,000. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Stock Down 2.1 %

Alpha Tau Medical stock traded down $0.05 during midday trading on Thursday, hitting $2.38. 17,061 shares of the stock were exchanged, compared to its average volume of 34,710. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.07 and a current ratio of 12.07. Alpha Tau Medical Ltd. has a 1 year low of $2.15 and a 1 year high of $4.80. The company has a 50 day moving average price of $2.85 and a two-hundred day moving average price of $3.04.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. On average, research analysts anticipate that Alpha Tau Medical Ltd. will post -0.51 EPS for the current fiscal year.

Alpha Tau Medical Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.